Andersons pediatric cardiology 1478

rhythm.AmJCardiol.2014;114(6):869–874.
48.VignaC,etal.Leftatrialthrombusand
spontaneousecho-contrastinnonanticoagulated
mitralstenosis:atransesophageal
echocardiographicstudy.Chest.
1993;103(2):348–352.
49.PeverillRE,etal.Determinantsofincreased
regionalleftatrialcoagulationactivityin
patientswithmitralstenosis.Circulation.
1996;94(3):331–339.
50.RemenyiB,etal.Improvedlong-termsurvival
forrheumaticmitralvalverepaircomparedto
replacementintheyoung.WorldJPediatr
CongenitHeartSurg.2013;4(2):155–164.
51.LawrenceJG,etal.Acuterheumaticfeverand
rheumaticheartdisease:incidenceand
progressioninthenorthernterritoryofAustralia,
1997to2010.Circulation.2013;128(5):492–
501.
52.BaskervilleCA,etal.Infectiveendocarditisand
rheumaticheartdiseaseinthenorthofAustralia.
HeartLungCirc.2012;21(1):36–41.
53.RHDAustralia(ARF/RHDwritinggroup)
NationalHeartFoundationofAustraliaandthe
CardiacSocietyofAustraliaandNewZealand,
Australianguidelineforprevention,diagnosis
andmanagementofacuterheumaticfeverand


rheumaticheartdisease(2ndedition).2012.
54.LennonD,WilsonN,SharpeN,LiddelR.New

ZealandGuidelinesforRheumaticFever:
Diagnosis,ManagementandSecondary
PreventionofAcuteRheumaticFeverand
RheumaticHeartDisease:2014.[cited2017
16thofSeptember2017;Availablefrom:]
2014.
55.NishimuraRA,etal.2017AHA/ACCfocused
updateofthe2014AHA/ACCguidelineforthe
managementofpatientswithvalvularheart
disease:AreportoftheAmericancollegeof
Cardiology/Americanheartassociationtask
forceonclinicalpracticeguidelines.Circulation.
2017;135(25):e1159–e1195.
56.WHOExpertConsultationonRheumaticFever
andRheumaticHeartDisease(2001:Geneva
Switzerland),Rheumaticfeverandrheumatic
heartdisease:reportofaWHOExpert
Consultation,Geneva,29October–1November
2001.WHOTechnicalReportSeries;923.WHO
TechnicalReportSeries;923.2004,Geneva:
WorldHealthOrganization.
57.ManyembaJ,MayosiBM.Penicillinfor
secondarypreventionofrheumaticfever.


CochraneDatabaseSystRev.2002;(3)
[CD002227].
58.WyberR,etal.BenzathinepenicillinGforthe
managementofRHD:concernsaboutquality
andaccess,andopportunitiesforintervention

andimprovement.Globalheart.2013;8(3):227–
234.
59.RemenyiB,etal.Positionstatementoftheworld
heartfederationonthepreventionandcontrolof
rheumaticheartdisease.NatRevCardiol.
2013;10(5):284–292.
60.JanuaryCT,etal.2014AHA/ACC/HRS
guidelineforthemanagementofpatientswith
atrialfibrillation:areportoftheAmerican
collegeofCardiology/Americanheart
associationtaskforceonpracticeguidelinesand
theheartrhythmsociety.JAmCollCardiol.
2014;64(21):e1–e76.
61.Regitz-ZagrosekV,etal.ESCguidelinesonthe
managementofcardiovasculardiseasesduring
pregnancy:thetaskforceonthemanagementof
cardiovasculardiseasesduringpregnancyofthe
Europeansocietyofcardiology(ESC).Eur
HeartJ.2011;32(24):3147–3197.
62.WilkinsG,etal.Percutaneousballoondilatation
ofthemitralvalve:ananalysisof
echocardiographicvariablesrelatedtooutcome